Addex Unveils Research on mGlu7 Targeting for Anxiety Treatment
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5d ago
0mins
Should l Buy ADXN?
Source: Newsfilter
- Research Publication: Addex Therapeutics published findings in Molecular Psychiatry indicating that targeting metabotropic glutamate receptor 7 (mGlu7) with negative allosteric modulators could be transformative for treating anxiety and post-traumatic stress disorder (PTSD), highlighting innovative prospects in this field.
- Mechanism of Action: In the study, ADX71743 effectively disrupted the reconsolidation of fear memories in rodent models, demonstrating the drug's ability to significantly decrease fear reinstatement within a defined time window after memory recall, offering a new therapeutic avenue that may reduce reliance on traditional medications.
- Cross-Species Validation: Electrophysiological analyses revealed similar synaptic effects of ADX71743 in both rat and human brain tissues, enhancing understanding of mGlu7 target engagement and providing early translational validation for central nervous system drug development.
- Broad Market Potential: The research findings not only offer a new direction for drug development in treating anxiety and trauma-related disorders but also have the potential to enhance Addex's competitive position in the neuropsychiatric market, further solidifying its standing in the biopharmaceutical industry.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ADXN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ADXN
About ADXN
Addex Therapeutics Ltd is a Switzerland-based clinical-stage pharmaceutical company. The Company focuses on development and commercialization of orally available small molecule drugs known as allosteric modulators for neurological disorders. The Company’s clinical programs pipeline include dipraglurant (mGlu5 NAM), which is Phase 2a placebo-controlled clinical trial for Parkinson's disease levodopa-induced dyskinesia (PD-LID), and is being prepared to enter registration trials for PD-LID, and ADX71149 (mGlu2 positive allosteric modulator or PAM), which is being developed in collaboration by its partner Janssen Pharmaceuticals, Inc to treat schizophrenia and anxious depression. It also is advancing several preclinical programs, including GABABPAM for pain, overactive bladder and other disorders, mGlu7 NAM for post-traumatic stress disorder, mGlu2 NAM for mild neurocognitive disorders, mGlu4 PAM for Parkinson’s disease and mGlu3 PAM for neurodegenerative disorders.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Addex Unveils Research on mGlu7 Targeting for Anxiety Treatment
- Research Publication: Addex Therapeutics published findings in Molecular Psychiatry indicating that targeting metabotropic glutamate receptor 7 (mGlu7) with negative allosteric modulators could be transformative for treating anxiety and post-traumatic stress disorder (PTSD), highlighting innovative prospects in this field.
- Mechanism of Action: In the study, ADX71743 effectively disrupted the reconsolidation of fear memories in rodent models, demonstrating the drug's ability to significantly decrease fear reinstatement within a defined time window after memory recall, offering a new therapeutic avenue that may reduce reliance on traditional medications.
- Cross-Species Validation: Electrophysiological analyses revealed similar synaptic effects of ADX71743 in both rat and human brain tissues, enhancing understanding of mGlu7 target engagement and providing early translational validation for central nervous system drug development.
- Broad Market Potential: The research findings not only offer a new direction for drug development in treating anxiety and trauma-related disorders but also have the potential to enhance Addex's competitive position in the neuropsychiatric market, further solidifying its standing in the biopharmaceutical industry.
See More
Addex's Spin-Out Neurosterix Initiates Phase 1 Study of NTX-253 for Schizophrenia
- Clinical Trial Launch: Addex Therapeutics' spin-out Neurosterix has initiated a Phase 1 clinical study of NTX-253, aimed at evaluating its safety and tolerability in healthy volunteers, marking a significant advancement in the treatment of schizophrenia.
- Funding Background: Neurosterix was spun out from Addex in April 2024, raising $65 million in Series A financing, demonstrating strong market interest in its novel small molecule allosteric modulators and enhancing its research capabilities.
- Innovative Therapy Potential: NTX-253, as a selective positive allosteric modulator of the M4 receptor, may offer a differentiated efficacy and safety profile compared to traditional dopamine antagonists, indicating a new direction in schizophrenia treatment.
- Market Outlook: By selectively modulating the M4 receptor, NTX-253 is expected to reduce psychotic symptoms while avoiding the side effects associated with traditional medications, potentially securing a significant position in the schizophrenia treatment market.
See More
Addex Amends $3.3 Million At-The-Market Offering Agreement
- Agreement Amendment: Addex Therapeutics has amended its At-The-Market Offering Agreement with H.C. Wainwright & Co., allowing for the sale of ADSs up to an aggregate offering price of $3.3 million, enhancing financial flexibility to support R&D for neurological disorders.
- Sales Commission Structure: Under the new agreement, Addex will pay H.C. Wainwright & Co. a 3% sales commission, which will impact the company's liquidity and potentially influence future R&D investments.
- Market Sales Method: H.C. Wainwright & Co. will sell ADSs through legally permitted market methods, ensuring that the company can flexibly adjust its sales strategy based on market conditions, thereby optimizing capital utilization.
- No Sales Obligation: Addex is not obligated to sell ADSs, providing the flexibility to make strategic decisions based on market conditions and internal needs, thus reducing financial risk.
See More
Addex Amends ATM Agreement with H.C. Wainwright for $3.3M Offering
- Financing Plan Revision: Addex Therapeutics announced an amendment to its ATM Agreement with H.C. Wainwright & Co., allowing for the sale of ADSs with an aggregate offering price of up to $3.3 million, aimed at enhancing funding flexibility to support the development of neurological disorders.
- Sales Commission Structure: Under the new agreement, Addex will pay H.C. Wainwright a 3% sales commission, a structure that incentivizes the agent to actively promote the sale of ADSs, potentially accelerating capital raising efforts.
- Market Sales Flexibility: Addex retains the flexibility to determine the timing and quantity of ADS sales based on market conditions and company needs, which will help the company optimize its financing strategy in an uncertain market environment.
- Risk Management Measures: The agreement includes customary indemnification and contribution rights, ensuring that Addex can effectively manage potential legal risks during the sales process, thereby protecting the company's long-term interests.
See More
UiPath Shares Rise Approximately 9%; Check Out 20 Stocks Making Moves in Premarket Trading
UiPath Financial Results: UiPath Inc. shares rose 8.7% in pre-market trading after reporting third-quarter adjusted earnings of 16 cents per share and revenue of $411.11 million, both exceeding estimates.
Other Gainers: Several stocks saw significant pre-market gains, including Polyrizon Ltd (+158.1%), Nauticus Robotics, Inc (+34%), and Picard Medical, Inc (+22.3%), driven by positive news and developments.
Notable Losers: Virax Biolabs Group Ltd fell 16.2% after announcing a private placement, while Treasure Global Inc declined 13.3% following a reverse stock split and Nasdaq delisting notification.
Market Overview: The pre-market trading session showed a mix of gains and losses across various stocks, with some companies like Axogen, Inc and Hyster-Yale, Inc also experiencing notable increases.
See More
Addex Reports Q3 2025 Financial Results with CHF 1.58M Net Loss
- Revenue Decline: Addex reported Q3 2025 income of CHF 505,800, down CHF 80,000 year-over-year, primarily due to the completion of the R&D collaboration phase with Indivior, impacting revenue streams significantly.
- R&D Expense Reduction: The company incurred R&D expenses of CHF 228,000 in Q3 2025, a slight increase from CHF 204,000 in the same quarter last year, indicating ongoing investment in the GABAB PAM chronic cough clinical candidate despite the completion of earlier phases.
- Widening Net Loss: As of September 30, 2025, Addex's net loss reached CHF 1.577 million, an increase of CHF 49,000 from CHF 1.528 million in the prior year, primarily driven by increased losses from its investment in Neurosterix US Holdings LLC.
- Cash Flow Situation: Cash and cash equivalents decreased to CHF 2.187 million as of September 30, 2025, down CHF 1.162 million from CHF 3.349 million a year earlier, reflecting cash outflow pressures from operational activities.
See More
Addex Unveils Research on mGlu7 Targeting for Anxiety Treatment
- Research Publication: Addex Therapeutics published findings in Molecular Psychiatry indicating that targeting metabotropic glutamate receptor 7 (mGlu7) with negative allosteric modulators could be transformative for treating anxiety and post-traumatic stress disorder (PTSD), highlighting innovative prospects in this field.
- Mechanism of Action: In the study, ADX71743 effectively disrupted the reconsolidation of fear memories in rodent models, demonstrating the drug's ability to significantly decrease fear reinstatement within a defined time window after memory recall, offering a new therapeutic avenue that may reduce reliance on traditional medications.
- Cross-Species Validation: Electrophysiological analyses revealed similar synaptic effects of ADX71743 in both rat and human brain tissues, enhancing understanding of mGlu7 target engagement and providing early translational validation for central nervous system drug development.
- Broad Market Potential: The research findings not only offer a new direction for drug development in treating anxiety and trauma-related disorders but also have the potential to enhance Addex's competitive position in the neuropsychiatric market, further solidifying its standing in the biopharmaceutical industry.
See More
Addex's Spin-Out Neurosterix Initiates Phase 1 Study of NTX-253 for Schizophrenia
- Clinical Trial Launch: Addex Therapeutics' spin-out Neurosterix has initiated a Phase 1 clinical study of NTX-253, aimed at evaluating its safety and tolerability in healthy volunteers, marking a significant advancement in the treatment of schizophrenia.
- Funding Background: Neurosterix was spun out from Addex in April 2024, raising $65 million in Series A financing, demonstrating strong market interest in its novel small molecule allosteric modulators and enhancing its research capabilities.
- Innovative Therapy Potential: NTX-253, as a selective positive allosteric modulator of the M4 receptor, may offer a differentiated efficacy and safety profile compared to traditional dopamine antagonists, indicating a new direction in schizophrenia treatment.
- Market Outlook: By selectively modulating the M4 receptor, NTX-253 is expected to reduce psychotic symptoms while avoiding the side effects associated with traditional medications, potentially securing a significant position in the schizophrenia treatment market.
See More
Addex Amends $3.3 Million At-The-Market Offering Agreement
- Agreement Amendment: Addex Therapeutics has amended its At-The-Market Offering Agreement with H.C. Wainwright & Co., allowing for the sale of ADSs up to an aggregate offering price of $3.3 million, enhancing financial flexibility to support R&D for neurological disorders.
- Sales Commission Structure: Under the new agreement, Addex will pay H.C. Wainwright & Co. a 3% sales commission, which will impact the company's liquidity and potentially influence future R&D investments.
- Market Sales Method: H.C. Wainwright & Co. will sell ADSs through legally permitted market methods, ensuring that the company can flexibly adjust its sales strategy based on market conditions, thereby optimizing capital utilization.
- No Sales Obligation: Addex is not obligated to sell ADSs, providing the flexibility to make strategic decisions based on market conditions and internal needs, thus reducing financial risk.
See More
Addex Amends ATM Agreement with H.C. Wainwright for $3.3M Offering
- Financing Plan Revision: Addex Therapeutics announced an amendment to its ATM Agreement with H.C. Wainwright & Co., allowing for the sale of ADSs with an aggregate offering price of up to $3.3 million, aimed at enhancing funding flexibility to support the development of neurological disorders.
- Sales Commission Structure: Under the new agreement, Addex will pay H.C. Wainwright a 3% sales commission, a structure that incentivizes the agent to actively promote the sale of ADSs, potentially accelerating capital raising efforts.
- Market Sales Flexibility: Addex retains the flexibility to determine the timing and quantity of ADS sales based on market conditions and company needs, which will help the company optimize its financing strategy in an uncertain market environment.
- Risk Management Measures: The agreement includes customary indemnification and contribution rights, ensuring that Addex can effectively manage potential legal risks during the sales process, thereby protecting the company's long-term interests.
See More
UiPath Shares Rise Approximately 9%; Check Out 20 Stocks Making Moves in Premarket Trading
UiPath Financial Results: UiPath Inc. shares rose 8.7% in pre-market trading after reporting third-quarter adjusted earnings of 16 cents per share and revenue of $411.11 million, both exceeding estimates.
Other Gainers: Several stocks saw significant pre-market gains, including Polyrizon Ltd (+158.1%), Nauticus Robotics, Inc (+34%), and Picard Medical, Inc (+22.3%), driven by positive news and developments.
Notable Losers: Virax Biolabs Group Ltd fell 16.2% after announcing a private placement, while Treasure Global Inc declined 13.3% following a reverse stock split and Nasdaq delisting notification.
Market Overview: The pre-market trading session showed a mix of gains and losses across various stocks, with some companies like Axogen, Inc and Hyster-Yale, Inc also experiencing notable increases.
See More
Addex Reports Q3 2025 Financial Results with CHF 1.58M Net Loss
- Revenue Decline: Addex reported Q3 2025 income of CHF 505,800, down CHF 80,000 year-over-year, primarily due to the completion of the R&D collaboration phase with Indivior, impacting revenue streams significantly.
- R&D Expense Reduction: The company incurred R&D expenses of CHF 228,000 in Q3 2025, a slight increase from CHF 204,000 in the same quarter last year, indicating ongoing investment in the GABAB PAM chronic cough clinical candidate despite the completion of earlier phases.
- Widening Net Loss: As of September 30, 2025, Addex's net loss reached CHF 1.577 million, an increase of CHF 49,000 from CHF 1.528 million in the prior year, primarily driven by increased losses from its investment in Neurosterix US Holdings LLC.
- Cash Flow Situation: Cash and cash equivalents decreased to CHF 2.187 million as of September 30, 2025, down CHF 1.162 million from CHF 3.349 million a year earlier, reflecting cash outflow pressures from operational activities.
See More
